Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 0% - Time to Sell?

Key Points

• Eupraxia Pharmaceuticals (NASDAQ:EPRX) shares are currently down 0%, trading at $5.27, with a significant drop in trading volume by 55% compared to its average.
• Analysts maintain a positive outlook on Eupraxia with a consensus price target of $11.00 and multiple ratings of "buy" or better from different equity research firms.
• The company's recent earnings report showed a loss of ($0.26) per share, which was worse than the consensus estimate of ($0.21), highlighting ongoing financial challenges.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report)'s share price was down 0% during trading on Tuesday . The stock traded as low as $5.15 and last traded at $5.27. Approximately 5,481 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 12,228 shares. The stock had previously closed at $5.27.

Analysts Set New Price Targets

Several equities research analysts have commented on EPRX shares. HC Wainwright reiterated a "buy" rating and issued a $12.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, August 20th. Canaccord Genuity Group started coverage on shares of Eupraxia Pharmaceuticals in a research report on Monday, June 16th. They issued a "speculative buy" rating on the stock. Finally, Cantor Fitzgerald started coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday, July 24th. They issued an "overweight" rating and a $11.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $11.00.

Eupraxia Pharmaceuticals Trading Down 0.0%

The company has a fifty day simple moving average of $5.36 and a 200-day simple moving average of $4.38. The stock has a market cap of $189.44 million, a price-to-earnings ratio of -6.20 and a beta of 1.50.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). As a group, analysts anticipate that Eupraxia Pharmaceuticals Inc. will post -0.67 earnings per share for the current year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Large investors have recently made changes to their positions in the business. Millennium Management LLC acquired a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at about $31,000. Raymond James Financial Inc. acquired a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at about $37,000. Quadrature Capital Ltd acquired a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at about $61,000. Bank of America Corp DE increased its holdings in shares of Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company's stock valued at $72,000 after purchasing an additional 10,059 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Eupraxia Pharmaceuticals by 593.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company's stock valued at $108,000 after purchasing an additional 16,017 shares during the period.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.